Nwam LLC Trims Stake in Pfizer Inc. (NYSE:PFE)

Nwam LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,415 shares of the biopharmaceutical company’s stock after selling 3,921 shares during the quarter. Nwam LLC’s holdings in Pfizer were worth $1,338,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at $26,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the period. Sierra Ocean LLC purchased a new position in shares of Pfizer during the 4th quarter valued at about $34,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $35,000. Finally, Joseph Group Capital Management increased its holdings in Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.3 %

Shares of NYSE PFE opened at $26.09 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The firm’s 50-day moving average price is $26.35 and its 200-day moving average price is $27.35. The stock has a market capitalization of $147.83 billion, a price-to-earnings ratio of 18.50, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.59%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 121.99%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PFE shares. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $33.00 target price on shares of Pfizer in a research report on Monday, February 10th. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.